

MEDI-CAL DRUG USE REVIEW (DUR) BOARD

State of California DEPARTMENT OF HEALTH CARE SERVICES

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, November 15, 2016**, at the following location:

Department of Health Care Services
1500 Capitol Avenue
Training Rooms B+C
Sacramento, CA 95814

Medi-Cal Drug Use Review Board
Meeting Agenda
November 15, 2016
9:30 AM-12:30 PM

Report Type*	Agenda Item	Presenter	Time
C	1. Welcome/Introduction	Pauline Chan, RPh, MBA	930-945
A	2. Call to Order/Review and Approval of Previous Minutes from September 20, 2016	Robert Mowers, PharmD	945-950
	3. Old Business		
A	a. Review of Action Items from Previous Board Meeting: <ul style="list-style-type: none"> i. Opioid Quantity Limit Policy ii. State Opioid Workgroup iii. FFY 2015 DUR Annual Report to CMS iv. Educational Outreach: Asthma v. Educational Outreach: Buprenorphine vi. Educational Outreach: Metabolic Monitoring vii. Retrospective DUR Review: Proton-pump Inhibitors 	Pauline Chan, RPh, MBA	950-1005
	4. New Business		
R/A/D	a. Board Activities <ul style="list-style-type: none"> i. Buprenorphine Study Proposal 	DUR Board Randall Stafford, MD, PhD	1005-1010 1010-1020

R/A	<ul style="list-style-type: none"> b. Quarterly Report: 3Q2016 (July – September 2016) c. Review of Physician Administered Drugs (PADs): 2Q2016 (April – June 2016) d. Prospective DUR <ul style="list-style-type: none"> i. Review of DUR Alerts for New GCNs: 3Q2016 ii. Section 25 Update – Therapeutic Categories e. Review of DUR Educational Outreach to Providers <ul style="list-style-type: none"> i. Update: Metabolic Monitoring Letter - 2016 ii. Update: Buprenorphine Letter 	Amanda Fingado, MPH	1020-1050
R/A/D	<ul style="list-style-type: none"> f. Retrospective DUR <ul style="list-style-type: none"> i. Review of Retrospective DUR Criteria: Hepatitis C Virus (HCV) Drugs ii. Review of Retrospective DUR Criteria: New Additions to the Medi-Cal List of Contract Drugs (FFY 2015) iii. Review of Retrospective DUR Criteria: Concomitant use of Opioids and Benzodiazepines g. Review of DUR Publications <ul style="list-style-type: none"> i. DUR Educational Alert (September, 2016): Vaccine Update ii. Discussion/Recommendations for Future Bulletins 	Shalini Lynch, PharmD	1050-1130
R/D	<ul style="list-style-type: none"> h. Global Data Sharing (state & counties) and Public Reporting of Psychotropic Medication Use in Foster Care Children & Youth 	Akhtar Khan, PhD, Chief, Research Services, CDSS	1130-1150
R/A/D	<ul style="list-style-type: none"> i. Overview of the Institute for Clinical and Economic Review (ICER) 	Stephen Pearson, MD, MSc, President, ICER	1150-1205
R/A/D	<ul style="list-style-type: none"> j. Pharmacy Update <ul style="list-style-type: none"> i. CMS Update ii. Academic Detailing Conference iii. Medi-Cal Managed Care Pharmacy Directors Meeting iv. DHCS Quality Strategy v. SB 238 Foster Care Psychotropic Medications vi. CDPH Collaboration: Improve Pre-natal Vitamin Use 	Pauline Chan, RPh, MBA	1205-1225
C	5. Public Comments		1225-1230
	6. Consent Agenda		
I	<ul style="list-style-type: none"> a. Meeting feedback b. Next meeting: February 21, 2017 9:30 AM -12:30 PM Xerox State Healthcare, LLC 840 Stillwater Road, Mendocino Room West Sacramento, CA 95605 c. DUR Board Meeting Dates for 2017: Tuesday, May 16, 2017 Tuesday, September 19, 2017 Tuesday, November 21, 2017 		
	7. Adjournment		1230

* REPORT TYPE LEGEND: **A: Action; R: Report; I: Information; C: Comment; D: Discussion**

** Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu Web site (http://files.medi-cal.ca.gov/pubsdoco/dur/dur_home.asp).